Receptor Tyrosine Protein Kinase ERBB3 Market to Emerge at a Rapid Pace during the Forecast Period

Mon, 12 October 2020 9:56

Targeted therapy has revolutionized the treatment landscape of various types of cancer. Currently, HER3 based drugs are not available in the market or have not received any approval from the FDA. However, several American and European players are continuously working to seek approval for HER3 based drugs, and they are heavily investing in advanced technology and R&D activities for product innovation and development. The HER3-based drugs are expected to enter the market by 2025, which is likely to revolutionize cancer treatment across Europe and America.

PIPELINE PRODUCTS

Name

Research code

Research

phase

Company

Indications

KTN-3379

KTN-3379; CDX-3379, KTN3379; CDX3379

Phase Ⅱ

Med Immune, Koll tan

KTN-3379

AllitinibTosylate

AST-6; ALS-1306; AST-1306

Phase Ⅱ

Shanghai Allist Pharmaceuticals

AllitinibTosylate

AC-480

AC-480; BMS-599626, AC480; BMS599626, AC 480; BMS 599626

Phase Ⅰ

Ambit biosciences

AC-480

Patritumab

AMG-888; U3-1287, AMG888, U31287

Phase Ⅲ

Daiichi Sankyo, Amgen

Patritumab

SPC-3920

SPC-3920; EZN-3920

Preclinical

Roche

SPC-3920

Seribantumab

MM-121; SAR-256212; 1N3L70MDFX (UNII code)

Phase Ⅱ

Merrimack, Sanofi

Seribantumab

Sapitinib

AZD-8931

Phase Ⅱ

AstraZeneca

Sapitinib

ISU-104

ISU-104

Phase Ⅰ

ISU Abxis

ISU-104

In the last few years, the global market has witnessed significant growth in the prevalence of various types of cancer across the globe. To address the dire situation, numerous players are constantly working on drug development and FDA approval. Currently, several HER3 drugs are in the pipeline and waiting for FDA approval. The study suggests that only HER3 acting drugs may not be that effective, but a combination with any chemotherapy drug can become a prominent option to treat cancers. Apart from this, many players are putting efforts into developing monoclonal antibodies against HER3.

We believe that rapidly growing drug resistance is one of the prime factors for drug failure as it limits the efficacy of many targeted therapies, including mono-/bispecific antibodies and small-molecule inhibitors. As per the clinical studies and findings, it is suggested that concomitant suppression of HER3 with other receptor tyrosine kinases (RTKs), such as EGFR family members, may appear to be helpful in attaining better clinical benefits. Moreover, the combination of HER-2 and HER-3 can offer a promising opportunity for treating colorectal cancer in the years to come.

Got questions about your regional growth of

Receptor Tyrosine Protein Kinase ERBB3 Market?

Just drop us a line or call on +1 646 480 7505

Key Highlights

  • The Elgemtumab segment is expected to dominate the market
  • North America’sreceptor tyrosine-protein kinase ERBB 3 market is expected to dominate during the forecast period, owing to the presence of key firms that are actively investing in umpteen clinical trials and research activities to seek approval for HER3 for treating cancer

Key Players

  • 14NER Oncology Inc.
  • AstraZeneca
  • AVEO Pharmaceuticals, Inc.
  • OriGene Technologies, Inc.
  • Roche
  • Cell Signaling Technology Inc.
  • GlaxoSmithKline plc. Merus
  • ACROBiosystems
  • Sino Biological Inc
  • Novartis AG

Receptor Tyrosine Protein Kinase ERBB 3 Market: Segmentation

By Product Type

  • BA 0702
  • CDX 3379
  • Elgemtumab
  • ETBX 031

By Application

  • Non-Small Cell Carcinoma
  • Solid Tumor
  • Melanoma
  • Colorectal Cancer

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Central and South America and the Caribbean
  • The Middle-East and Africa

 

" Crucial Insights The Report Provides:"

* Known and Unknown Adjacencies Influencing the Growth of Market

* Explorable Revenue Sources

* Customer Behaviour Analysis

* Target Partners

* Customized Geographical Data Based on Customers as well as Competitors

* Analysis of Market Size and CAGR between the Forecast Periods

View Full Report Buy This Report Now